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Abstract
Hepatosplenic T cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this 
disease are unknown. Through whole exome sequencing of 68 HSTLs, we define recurrently 
mutated driver genes and copy number alterations in the disease. Chromatin modifying genes 
including SETD2, INO80 and ARID1B were commonly mutated in HSTL, affecting 62% of 
cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%) for 
which there currently exist potential targeted therapies. In addition, we noted less frequent events 
in EZH2, KRAS and TP53. SETD2 was the most frequently silenced gene in HSTL. We 
experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found 
that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell 
survival in HSTL. Our work thus defines the genetic landscape of HSTL and implicates novel 
gene mutations linked to HSTL pathogenesis and potential treatment targets.
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INTRODUCTION
Hepatosplenic T cell lymphoma (HSTL) is a rare type of peripheral T cell lymphoma 
(PTCL) that affects fewer than 2% of all lymphoma patients each year. Compared to other 
PTCL subtypes, HSTL is striking for its predilection for young individuals and a dismal 
prognosis; most HSTL patients succumb to their disease in less than a year (1,2).
While the vast majority of PTCLs arise from αβ T cells, HSTL arises predominantly 
(>80%) from γδ T cells. Immunosuppression is a major risk factor for HSTL, particularly in 
the setting of organ transplantation and exposure to thiopurines or TNF-α antagonists, but 
most HSTL cases arise sporadically in the absence of any known factors. Most HSTL 
patients are treated with combination chemotherapy and, when feasible, bone marrow 
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transplantation, but relapses are frequent and the overwhelming majority of patients 
succumb to HSTL.
The most frequent known genetic abnormalities in HSTL are isochromosome 7q (iso7q) 
(3,4) and trisomy 8 (5,6), but the role of somatic mutations and other genomic alterations in 
HSTL has yet to be defined. Application of next generation sequencing in other peripheral T 
cell lymphomas (7–18) has revealed a strikingly heterogeneous genetic landscape 
implicating over a dozen different genetic alterations including novel therapeutic targets. 
Similar systematic studies in HSTLs have been lacking.
In this study, we sought to define the genetic landscape of HSTL through whole exome 
sequencing of 68 HSTL cases, including 20 cases with paired germline DNA. We found that 
HSTLs have a distinct pattern of genetic alterations. In addition to iso7q and trisomy 8, 
HSTLs manifested frequent mutations in the genes SETD2, INO80, STAT5B, SMARCA2, 
TET3, and PIK3CD. Interestingly, mutations that occur frequently in other T cell 
lymphomas in genes such as RHOA, CD28 and CCR4 were notably absent or occurred at 
much lower frequency in HSTLs. Finally, through functional studies in HSTL cells, we 
demonstrate SETD2 to be a novel tumor suppressor gene that mediates increased cellular 
proliferation in HSTL. In addition, we found that mutations in STAT5B and PIK3CD 
activate critical signaling pathways important to cell survival in HSTL.
To our knowledge, this study is the largest series of HSTL patients ever described and 
defines in detail the genetic landscape of mutations, implicating a number of novel genes 
and molecular pathways in this disorder.
RESULTS
Whole exome sequencing of HSTL identifies gene coding mutations and chromosomal 
copy number alterations
We performed whole exome sequencing on 68 primary HSTL tumors, 20 with paired normal 
tissue, and 2 HSTL cell lines (i.e. total 90 exomes). The bioinformatics methods are 
described more comprehensively in the Supplementary Methods. The 20 cases with paired 
normal tissue were deemed a “discovery set” and the remaining samples, a “validation set”. 
Only genes found to be somatically mutated in the discovery set were initially considered as 
candidate driver genes in HSTL.
As expected, HSTL patients in our study had a dismal prognosis with a median survival of 
11.9 months following the diagnosis. The majority (63%) of the patients died within two 
years of diagnosis (Figure 1a). HSTL driver genes are depicted as a heat map in Figure 1b. 
The distribution of these gene mutations in the different HSTL cases is shown in Figure 1b 
and the frequency of these events is shown in Figure 1c. Chromatin modifying genes 
constituted the most frequently mutated group of genes in HSTL, accounting for 62% of the 
cases. SETD2 was the most commonly mutated chromatin modifying gene in HSTL (24 
mutations found in 17 patients) with 71% (12/17) of the cases manifesting at least one loss-
of-function (nonsense or frameshift) mutation. SETD2 showed strong selection for protein 
altering mutations, with only one synonymous mutation observed. Other frequently mutated 
McKinney et al. Page 2
Cancer Discov. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chromatin modifier genes included INO80 (21%), TET3 (15%), and SMARCA2 (10%). 
Mutations in signaling pathways comprised the next most common group of mutations and 
manifested as predominantly missense mutations in STAT5B, STAT3, and PIK3CD. In 
addition, we observed mutations in TP53, UBR5 and IDH2. Among these gene mutations, 
only those in STAT5B and STAT3 have been described in HSTLs previously (19,20). We 
verified the accuracy of genetic variant identification from our deep sequencing data by 
performing Sanger sequencing in 78 individual variant events from the same cases 
(Supplementary Table S1). Representative plots from Sanger validation are shown in 
Supplementary Figure S1a–b. We found that Sanger sequencing agreed with our methods in 
88% of the variants, confirming that our laboratory methods for deep sequencing and 
computational methods for identifying genetic variants generated accurate results. We 
identified 13 somatically mutated HSTL driver genes (Supplementary Table S2) using a 
model that relies on the frequencies of non-synonymous events in HSTL, the size of the 
gene, the rate of non-synonymous variation occurring the in gene in healthy controls and the 
predicted impact of the altered amino acid(s) as we have described previously (21–23).
Estimates of cancer cell fraction based on observed allele frequencies for each driver gene 
are shown in Supplementary Figure S2a. STAT3, PIK3CD, and SETD2 show the highest 
proportion of clonal events among the driver genes. We compared cancer cell fractions 
(allele frequency adjusted for tumor purity) for pairs of mutations occurring in the same 
sample (Supplementary Figure S2b), and found considerable heterogeneity in the genes that 
arose as predominant drivers in different cases. In addition, we examined mutation data for 
the presence of well-characterized driver mutations, even in the absence of a clear somatic 
event in the discovery set. We identified rare mutations in a number of known driver genes 
including KRAS (N=3) and CREBBP (N=2) that have been described in other cancers. 
Additional somatic mutations found and putative driver mutations are shown in 
Supplementary Table S3.
We further examined chromosomal alterations in HSTLs (Figure 1d). Alterations in 
chromosome 7 were the most common genetic abnormality in HSTLs affecting 47% 
(Supplementary Table S4, Supplementary Figures S3) of our cases. While the majority of 
cases manifested clearly as iso7q with losses of chromosome 7p and gains of 7q, there were 
five cases with only 7q amplifications. Supplementary Figure S3 shows the exact regions of 
chromosome 7 altered in all the affected cases, which are complete arm level alterations in 
the vast majority of cases. Trisomy 8 or amplifications of 8q were the next most frequent 
chromosomal aberration (31%), frequently co-occurring with chromosome 7 alterations (18 
overlapping cases). We also found losses in chromosome 10q (19%) and gains in 
chromosome 1q (13%) occurred in a significant proportion of HSTL cases. The only driver 
gene that is located within these copy number regions is UBR5, on chromosome 8q. We did 
not find any mutations that clearly overlapped or occurred independently of these 
chromosomal alterations. The median number of genetic alterations per sample in these 
driver mutation and copy number events was three (Figure 1e).
We also sequenced the only described HSTL cell lines DERL2 and DERL7, which are 
derived from the same primary HSTL tumor (24). Their genetic profiles were nearly 
identical, and representative of the HSTL tumors, with mutations in STAT5B, ARID1B, 
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SMARCA2, and TP53, as well as copy number alterations of isochromosome 7q, trisomy 8, 
loss of 10p, and gain of 1q (Supplementary Figure S4a–b).
Clinical Characteristics of HSTL patients
The patients’ gender, T cell receptor type and response to initial therapy are shown for 
comparison to the molecular features in Figure 1f. The clinical characteristics of our patients 
are summarized in Table 1.
Briefly, the median age was 42 (range 4–72). As expected, male patients comprised the 
majority (71%) of the cohort with a worse prognosis than females (p=0.05, log rank test). 
Elevated LDH levels and ECOG performance status (p=0.002 for both, log rank test) are the 
clinical variables most clearly associated with outcome. 80% of cases were of the γδ T cell 
receptor (TCR) type, but no survival association was seen with the TCR type. Patients with a 
complete response (CR) to initial treatment and those patients who received an autologous 
or allogenic transplant following initial treatment had significantly improved outcomes 
(p=0.001 and 0.014, respectively). Supplementary Table S5 contains complete 
clinicopathologic data, and Supplementary Figure S5 shows the Kaplan-Meier plots for 
these and additional clinical variables.
We also investigated the association of genetic mutations and copy number alterations with 
clinical outcome in an exploratory fashion. The most robust survival associations within the 
genetic features were found with the copy number alterations on chromosome 7 and 8 
(p=0.051 and p=0.024, respectively), which were both associated with worse outcomes. 
Kaplan-Meier plots for these molecular covariates are shown in Supplementary Figure S6. 
Additional survival analyses are presented in the Supplementary Methods.
These data add clarity to other studies that have postulated links between clinicopathologic 
or molecular features and patient level outcomes in HSTL (Supplementary Table S6). 
Supplementary Table S7 shows the similarity of our patient cohort to those previously 
reported.
Genetic differences between HSTL and other T cell and B cell lymphomas
HSTL has a distinct clinical presentation and response to therapy compared to other B and T 
cell lymphomas. We next investigated whether HSTLs are also genetically distinct from 
these tumors. We compared the frequencies of the most recurrently mutated genes in HSTL 
to other lymphomas studied by whole exome sequencing including the T cell lymphomas 
PTCL not otherwise specified (PTCL NOS) (8), angioimmunoblastic T cell lymphoma 
(AITL) (8,12), cutaneous T cell lymphoma (CTCL) (13,16–18), adult T cell lymphoma 
(ATL) (15), anaplastic large cell lymphoma (ALCL) (14), and NK T cell lymphoma 
(NKTCL) (10), as well as the B cell lymphomas diffuse large B cell lymphoma (DLBCL) 
(23,25,26), Burkitt lymphoma (BL) (21,27,28) and mantle cell lymphoma (MCL) (22,29). 
The mutational frequencies for these lymphoma types are shown in Figure 1g and 
Supplementary Table S8, and additional HSTL mutation details shown in Supplementary 
Table S9.
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We found that mutations in SETD2, INO80, TET3 and STAT5B occurred almost exclusively 
in HSTLs (p<0.05 in each case, Fisher’s exact test), compared to other T and B cell 
lymphoma types. On the other hand, mutations in RHOA, a defining feature of PTCL NOS 
and AITL, never occurred in HSTL cases. Additionally, HSTLs shared some mutations that 
have mostly been observed in B cell lymphomas including PIK3CD (23), UBR5 (30) and 
SMARCA2 (22). These data indicate that HSTLs have a unique profile of genetic mutations 
that distinguishes them from other non-Hodgkin lymphoma subtypes and may underlie its 
distinct clinical behavior.
Functional consequences of SETD2 silencing in HSTL
SETD2 was the most frequently silenced gene in HSTLs, affecting almost a third of the 
cases. The mutations in SETD2 occurred predominantly in exons 3, 10–12 and 19–21 
(Figure 2a). The Set2-Rpb1 interacting domain (SRI) domain (31) at the COOH-terminus of 
the SETD2 protein product was the most frequently mutated protein domain, but a number 
of mutations were also interspersed among different domains. We noted that 67% (16/24) of 
the mutations in SETD2 occurring in the 17 HSTL patients were either frameshift or 
nonsense mutations. 44% (7/17) of the SETD2 mutated patients had more than one mutation 
in SETD2. We analyzed the potential biallelic nature of the SETD2 mutations in one of these 
patients, by analysis of paired-end exome sequencing reads and Sanger sequencing. We 
found that the two SETD2 mutations in that case occurred on mutually exclusive DNA 
strands suggesting a biallelic event (Supplementary Figure S7). Our genetic data thus 
indicate that SETD2 has a tumor suppressor function in HSTLs with frequent loss-of-
function mutations that may occur in biallelic fashion. No expression differences in SETD2 
were seen between wildtype and SETD2 mutant samples (Supplementary Figure S8).
SETD2 functions as a methyltransferase at lysine 36 of histone 3 and 4, catalyzing H3/4K36 
trimethylation at dimethyl sites. The gene has diverse functions related to cancer including 
tumor proliferation, sensing and repair of DNA damage, and other oncogenic changes in 
gene expression (32–37). To determine the functional consequences of SETD2 loss in 
HSTLs, we performed RNA interference experiments using lentiviral vectors expressing two 
different shRNAs targeting SETD2 in DERL2 HSTL cells. We observed robust knockdown 
of SETD2 mRNA expression in HSTL cells expressing the shRNAs targeting SETD2 
compared to non-silencing (scramble) control (Figure 2b). We further observed that loss of 
SETD2 mRNA expression was accompanied by reduced SETD2 protein expression along 
with loss of H3 lysine 36 trimethylation in the same cells (H3K36me3, Figure 2c).
We further measured the downstream effects of SETD2 knockdown by performing RNAseq 
to define gene expression profiles of HSTL DERL2 cells with knockdown of SETD2. We 
compared the expression profiles of cells with SETD2 knockdown through two different 
shRNAs and those expressing the non-silencing control shRNA in three independent 
replicates (Figure 2d). Through gene set enrichment analysis (38), we identified the 
pathways that were upregulated (FDR <0.25) in the setting of reduced SETD2 expression 
(Supplementary Table S10). We found that eight of the ten most significantly altered gene 
sets were related to proliferation or cell cycle progression (including G2M checkpoint genes 
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and core cell cycle genes as shown in Figure 2d), identifying proliferation as the major 
oncogenic process affected by SETD2 loss in HSTL cells.
We next tested the proliferative ability of HSTL cells with intact and reduced SETD2 
expression by performing colony-forming assays in cells expressing shRNAs targeting 
SETD2 as well as the non-silencing control. We found that the cells post SETD2 knockdown 
had more than two-fold increased colony formation (p<0.01, paired Wilcoxon-rank test) 
compared to control non-silencing cells with intact SETD2 expression (Figure 2e). We also 
examined the effects of SETD2 on cell proliferation using alamar blue cell quantitation 
assays and found that, compared to non-silencing control (Figure 2f), the HSTL cells 
expressing lower SETD2 have significantly higher proliferation and increased cell counts 
(p<0.01, paired Wilcoxon-rank test), consistent with its role as a tumor suppressor gene.
Our genetic and functional data thus implicate SETD2 as a novel tumor suppressor gene in 
HSTL and demonstrates that loss of function SETD2 mutations serve to increase 
proliferation in HSTL cells.
STAT5B, PIK3CD mutations and downstream signaling
STAT5B and STAT3 mutations have been previously reported in HSTL (19,20). We found 
somatic STAT5B and STAT3 mutations occurring mostly in a mutually exclusive manner 
(Supplementary Figure S9). Mutations in STAT5B and STAT3 occurred predominantly in 
their SH2 domains, consistent with previous reports showing mutations in this gene in HSTL 
and other malignancies. Many of the PIK3CD mutations (Figure 3a) occurred in analogous 
fashion to constitutively activating mutations in homologous regions of PIK3CA, which 
activates PI-3 kinase/AKT signaling in non-hematologic cancers (39).
Given this pattern of mutations, we hypothesized that STAT5B, STAT3, PIK3CD mutations 
in HSTL would constitutively activate downstream signaling pathways, and that mutant 
STAT5B and PIK3CD may potentially cooperate to maintain proliferation pathways within 
HSTL cells. To test this hypothesis, we first examined the effects of the STAT5B mutations 
through their overexpression in serum starved 293T cells (the HSTL cell line DERL2 is 
STAT5B-mutant). We found that the dominant hotspot mutations N642H and V712E were 
particularly efficacious in maintaining STAT5 phosphorylation, as were many of the other 
STAT5B mutants compared to the wild type or empty vector control cells (Figure 3b). 
Phosphorylated AKT or total AKT were not altered in these cells, indicating the STAT5B 
mutations directly enable phosphorylation of STAT5 that has been shown to have a number 
of downstream oncogenic effects (19).
We further investigated the impact of PIK3CD mutations on signaling in HSTL cells. We 
overexpressed three PIK3CD mutants (R38C, K111Q and N334K) found in HSTL tumors in 
DERL2 HSTL cells. In DERL2 cells overexpressing PIK3CD mutants, we found greatly 
increased phosphorylated AKT. In addition, we noted increased phosphorylated STAT5 
(pSTAT5) compared to cells with control constructs (Figure 3c), indicating potential 
cooperativity between PI-3 kinase and JAK-STAT signaling in maintaining downstream cell 
survival/proliferation signals.
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Next, we tested the ability of PI-3 kinase mutants to protect DERL2 HSTL cells from cell 
death under IL-2 deprivation/serum starvation conditions. After 24 hours of serum starvation 
and cytokine withdrawal, DERL2 cells bearing mutant PIK3CD constructs had significantly 
higher viability compared to those expressing wild type or empty vector controls (Figure 
3d). These data confirm that mutant PIK3CD could maintain cell viability and proliferation.
Finally, we tested the effects of PI-3 kinase and STAT5B signaling inhibition as a potential 
targeted strategy for treating HSTL. In DERL2 HSTL cells, we tested the effects of a MAP 
kinase inhibitor (selumetinib, an off-target control) as well as STAT5B inhibitor (with CAS 
285986-31-4), PI-3 kinase inhibitor (idelalisib), and combinations of the STAT5B and PI-3 
kinase inhibitors. We found that the MAP kinase inhibitor had no effect on cell growth, but 
the STAT5B inhibitor significantly attenuated cellular growth in vitro at 96 hours versus 
vehicle treatment control (Figure 3e). Notably, the addition of PI-3 kinase inhibition to 
STAT5B inhibition resulted in further reduction of cellular viability than either STAT5B or 
PI-3 kinase inhibition alone, indicating potential synergism interaction when targeting 
STAT5B/PI-3 kinase cooperativity in HSTL cells.
DISCUSSION
HSTL remains among the direst diagnoses any cancer patient can face. The young age of the 
patients and the general lack of progress in the treatment options or outcomes further 
compounds the grimness of the prognosis (40). A recognized risk factor for developing 
HSTL is the use of immune suppressive and immune modulatory therapies such as 
infliximab and azathioprine (41). The growing use of these therapies in rheumatologic and 
inflammatory conditions suggests that HSTL might become an increasingly larger concern 
in the future.
Our work indicates that the distinct clinical behavior of HSTL may originate from its distinct 
genetic profile. Compared to other T cell lymphomas, mutations in genes such as RHOA, 
CD28, CCR4 and other genes that are defining features of other T cell lymphomas are 
notably absent in HSTLs. Conversely, the most frequent HSTL mutations including SETD2, 
INO80, and PIK3CD, occur infrequently in other T cell lymphomas. STAT5B mutations 
have been described in primary cutaneous γδ PTCL (19), but are not mutated in most other 
T cell lymphomas derived from αβ T cells. Interestingly, STAT3 mutations are a frequent 
feature of a number of lymphomas including NKTCL (10) and diffuse large B cell 
lymphoma (25).
SETD2, a histone lysine methyltransferase, was the most frequently silenced gene in 
HSTLs. SETD2 has been described as a tumor suppressor gene in other malignancies 
including clear cell renal carcinoma (42), DLBCL (23), and in a subset of acute leukemias 
(43). Our genetic and experimental data identify SETD2 as a novel tumor suppressor gene in 
HSTL. Our experiments indicate that SETD2 mutations serve to increase proliferation in 
HSTL tumors. More work is needed to define the precise role of SETD2 in HSTL 
oncogenesis as well as its potential role in regulating T cell development.
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The recurrent genetic mutations in HSTL also suggest new therapeutic targets in the disease 
with new hope for these patients. The activating mutations in PI3KCD and STAT signaling 
genes provide a framework for identifying new therapies in this disease. The rareness of the 
disease makes it unlikely that a comprehensive clinical trial can be performed; thus the 
clinical experience with potential off-label use of these targeted therapies should be carefully 
reported to inform future therapies in HSTL patients.
Thus, our data define the genetic landscape of HSTLs and implicates novel gene mutations 
linked to HSTL pathogenesis and therapeutic targets.
METHODS
Study design and sample selection
HSTL tumors and normal tissues were obtained from institutions that constitute the 
Hematologic Malignancies Research Consortium (44) and Tenomic Consortium (45). All 
cases were reviewed to verify the accuracy of the pathology diagnosis. Tumor samples were 
derived from FFPE tissues, and normal samples were from unaffected bone marrow, when 
available. Archival patient tumor and normal samples, as well as clinical data, were collected 
according to a protocol approved by the Duke University Institutional Review Board, which 
was exempt from informed consent, and in accordance with the Declaration of Helsinki.
Exome sequencing and derivation of genomic data
Briefly, genomic DNA was sheared to 250 bp and size/concentration were verified using 
Bioanalyzer (Agilent Technologies). Sheared DNA was end-repaired, A-tailed, and ligated 
to Illumina paired-end adapters. The resulting libraries were amplified using Illumina PE 
specific primers. Samples were column purified and the size and quantity of the final 
libraries was determined using Bioanalyzer (Agilent Technologies). The resulting libraries 
were then hybridized for 24 hours to DNA baits provided in the SureSelect Human All Exon 
50MB kit (Agilent Technologies). The captured libraries were amplified and sequenced 
using the Illumina platform. FASTQs were aligned to the hg19 reference genome using 
BWA-MEM. Indel realignment and base quality recalibration are done with GATK tools. 
Variants were called using SAMtools mpileup on all samples. Somatic mutations in paired 
samples were called using Mutect. Variants were annotated with Annovar. Average 
sequencing depth throughout samples was 80×. Additional bioinformatic pipeline details as 
well as detailed, complete supplemental methods are in the Supplementary Methods.
Cell lines and cell culture
Human embryonal kidney 293T cells were obtained from the American Type Culture 
Collection (ATCC, obtained Sept. 2013) and maintained as a monolayer in DMEM with 
10% fetal bovine serum. Modified 293T cells (GP2 cells from Clontech, obtained June 
2012) were cultured in identical conditions. DERL2 and DERL7 cells (24) were obtained 
from Dr. Philippe Gaulard in Oct. 2013 and subjected to exome sequencing to confirm 
isochromosome 7q and their other known genetic markers. Cell lines were not otherwise 
authenticated and assumed to be authentic as they were obtained from the original supplier. 
Unless otherwise noted, DERL2 and DERL7 HSTL cells were cultured in 20% human AB 
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positive serum in 50 ng/mL IL2 (Peprotech). For gene overexpression experiments serum 
starvation was performed by washing cells with PBS twice then re-introducing cells to 
media without serum or cytokines followed by signaling or viability experiments.
Western blotting
For each sample, 106 cells were washed once in ice cold PBS and lysed in 150 microliters of 
RIPA buffer (Sigma) containing protease, phosphatase inhibitors (Roche) and 2 mM EDTA. 
Crude lysates were sonicated at 10% duty cycle, intensity 4, 200 cycles/burst on a Covaris S-
series device then centrifuged at 13,000 g for 10 minutes and supernatants were used for 
downstream experiments. 10–30 micrograms of protein were separated on 4–18% Bis-Tris 
gradient gels and transferred overnight to Immobilion PVDF membranes (Millipore) in Tris-
glycine buffer with 20% methanol at 30 V. Primary antibodies (anti-SETD2, anti-
H3K36me3, anti-STAT3, anti-phospho-STAT3, anti-STAT5, anti-phospho-STAT5, anti-
phospho-AKT, anti-GAPDH, all from Cell Signaling, and anti-p110 from abCam) were 
diluted 1:1000 in 5% BSA/TBS-T and bound overnight followed by washing and binding of 
HRP conjugated anti-rabbit antibody (Santa Cruz Biotechnology). Blots were developed 
using SuperSignal Pico chemiluminescent substrate (Thermo Scientific).
RNA Knockdown
Lentiviral pTRIPZ constructs (Open Biosystems) containing either a scrambled non-
silencing sequence as control, or a hairpin sequence targeting the SETD2 gene, were mixed 
with pVSV-G (46) and pPAX2 (Addgene #12259, from Didier Trono) and transfected into 
TLA-HEK-293T cells. Virus was harvested 72 hours post-transfection and concentrated by 
centrifugation at 90,000 g for 90 minutes at 4°C. DERL2 HSTL cells were infected with 
virus in the presence of 4 mg/mL of polybrene, using 5×106 cells per well in a 6-well plate 
by centrifugation at 1000 g for 60 minutes. Cells were selected by puromycin for 96 hours; 
then shRNA production was induced by doxycycline (1 g/mL replaced every 48 hours) for 
96 hours prior to downstream experimentation. Successful knockdown of SETD2 was 
confirmed by quantitative PCR (qPCR) and Western blot. RNA sequencing methods and 
derivation of gene expression profiles of HSTL cells with SETD2 or control shRNAs is 
described in the Supplementary Methods.
Lentiviral gene overexpression
mRNA from DERL2 HSTL cells was extracted and a corresponding cDNA library was used 
to amplify full length PIK3CD and STAT5B sequences which were ligated downstream of 
the CMV promoter at the PacI restriction site of the pQCXIP retroviral vector using PacI 
restriction sites on the flanking cloning primer used for gene amplication. cDNA constructs 
in pQCXIP plasmids were verified using Sanger sequencing and mutagenesis to yield 
desired mutant constructs was performed by PCR-technique using the NEB mutagenesis kit. 
Mutant cDNA expression clones were again verified by Sanger sequencing. Lentiviral 
particles were produced via pQCXIP co-transfection with VSV-G plasmid in GP2 293 cells 
and virus was harvested and cells transfected as described above of lentiviral shRNA 
constructs.
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Colony forming assays
DERL2 HSTL cells, exposed to doxycycline for >96 hours, were plated in 1000/mL in 
IMDM-based methylcellulose semi-solid media containing 50 ng/ML IL2, 25 ng/mL SCF 
and 1 mg/mL doxycycline. Cells were cultured for 4 weeks at 37°C and 5% CO2. 10% of 
media volume containing 10× concentrations of IL2, SCF and doxycycline was added every 
5 days. Once visible colonies formed, plates were photographed, and colonies were 
identified and counted.
Cellular proliferation assays
To measure cellular proliferation over time, cells were plated in 96-well plates, 5,000 cells/
well, in 220 μl of media in replicates with conditions varied according to the experimental 
design. Quantitation of the number of cells at each desired timepoint was accomplished by 
measured by adding 25 μl alamar blue to replicate wells and measuring fluorescence 
(excitation 430 nM, emission 490 nM) on a Tecan plate reader after 6 hours incubation of 
alamar blue with cells. Fluorescence values obtained in this manner were normalized to 
values obtained by adding alamar blue at time = 0 or at the commencement of the 
experiment in order to obtain values relative to proliferation over time.
Pharmacologic treatment of cell lines
The viability of DERL2 HSTL cells exposed to small molecule inhibitors was performed as 
previously described (47) with the exception that alamar blue fluorescence was measured 
instead of absorbance values post MTT and detergent incubation. Selumetinib was obtained 
from Selleck chemicals, STAT5B inhibitor (CAS 285985-31-4) was obtained from Millipore 
and idelalisib was obtained from Gilead biosciences. Controls included carrier control and 
10% DMSO control for 100% and 0% proliferation controls, respectively. After 3 days of 
incubation, 25 μl of alamar blue reagent was added to the cells, which were then incubated 
at 37 °C for 12h. Fluorescence values at 590 nm were assessed with a plate reader device 
(Tecan). Normalized proliferation (% viable cells) for each well was calculated as 
Normalized proliferation = (well absorbance − 10% DMSO control absorbance)/(carrier 
control absorbance − 10% DMSO control) or values were normalized to fluorescence values 
at baseline for cell line or drug assay experiments.
Statistics
Fisher’s exact test was used to compare mutation frequencies between lymphoma types and 
between subgroups of HSTL. The Cox proportional hazards model was used to test 
significance in survival associations with clinical and molecular covariates. Survival curves 
were drawn using the Kaplan-Meier method. Individual methods used for analysis of 
clinical, pathologic and mutational features and survival are listed in the Supplementary 
Methods.
Data Availability
Primary sequence data are available at the European Genome-phenome Archive (EGA) 
under accession number EGAS00001002182.
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Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF SIGNIFICANCE
We report the first systematic application of whole exome sequencing to define the 
genetic basis of hepatosplenic T cell lymphoma (HSTL), a rare but lethal disease. Our 
work defines SETD2 as a novel tumor suppressor gene in HSTL and implicates novel 
genes in the disease including INO80 and PIK3CD.
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Figure 1. Characterization of mutations, copy number, clinical data, and survival in HSTL cases
A. Kaplan-Meier curve for all HSTL cases with available survival data (n=47). Median 
survival is 11.9 months. Median follow-up is 4.2 years.
B. Heat map of mutated genes in HSTL (n=68). Each row represents a mutated gene in 
HSTL. Each column represents a patient sample. Blocks are color coded by functional type 
of mutation (orange: stopgain SNV; green: frameshift indel; purple: missense SNV; pink: 
nonframeshift indel; teal: synonymous). Samples are separated into discovery set (n=20) 
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with paired normal and validation set (n=48). Samples with more than one variant per gene 
are indicated with black dots on the block.
C. Number of cases affected per gene. Bars colored by most damaging mutation in each 
gene-sample pair.
D. Copy number alterations of chromosome 7p and 7q, 8p and 8q, 10p, and 1q. (light blue/
dark blue: chromosome 7, light red/dark red: chromosome 8, dark green: chromosome 10p, 
yellow: chromosome 1q)
E. Number of events per sample, including significant mutations and arm level copy number 
changes.
F. Heat map of clinical variables: gender (blue: male, pink: female), TCR type (light green: 
alpha-beta or light orange: gamma-delta), and response to initial treatment (red: 
CR=complete response, black: no complete response).
G. Mutation frequency (vertical bars) of genes in Hepatosplenic T Cell Lymphoma (HSTL, 
N=68): blue, Cutaneous T Cell Lymphoma (CTCL, N=37): dark purple, Anaplastic Large 
Cell Lymphoma (ALCL, N=23): magenta; Natural Killer/T Cell Lymphoma (NKTCL, 
N=25): pink, Adult T Cell Leukemia/Lymphoma (ATL, N=81): red, Angioimmunoblastic T 
Cell Lymphoma (AITL, N=28 or 9): orange, Peripheral T Cell Lymphoma (PTCL, N=22 or 
6): yellow, Diffuse Large B Cell Lymphoma (DLBCL, N=96): light blue, Burkitt Lymphoma 
(BL, N=59): light green, and Mantle Cell Lymphoma (MCL, N=56): dark green.
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Figure 2. Discovery and characterization of HSTL SETD2 mutations and function
A. Diagram of SETD2 gene exon model, protein domains, and HSTL mutations. Exon 
model shows 21 exons from the canonical transcript, which spread across 147 KB of 
genomic space. 24 SETD2 mutations are indicated at their amino acid position, color-coded 
by type of mutation (yellow: frameshift; red: nonsense; black: missense; blue: synonymous). 
Protein domains are indicated along the gene, color-coded by domain name (purple: AWS; 
pink: SET; green: PostSET; blue: Low Charge; orange: WW; dark red: SRI).
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B. SETD2 mRNA expression in SETD2 shRNA knockdown and non-silencing control in 
DERL2. p <0.01 for both SETD2 knockdowns vs. non-silencing (NS) control, average 
knockdown of >70%.
C. Immunoblot blot showing knockdown of SETD2 and H3K36me3 loss after SETD2 
shRNA induction in DERL2 cells. Results representative of three repeat experiments.
D. Heatmap of genes differentially expressed in DERL2 HSTL after SETD2 knockdown 
compared to non-silencing controls (left panel). Genes shown to have p<0.05 by Student’s t 
test of SETD2 knockdown versus control. Right panel depicts two pathways significantly 
upregulated in SETD2 knockdown based on gene set enrichment analysis (GSEA). Gene 
rank is based on t-statistic between control and knockdown samples. Enrichment score is 
shown on the y-axis as the gene list is traversed on the x-axis.
E. Results of methylcellulose colony formation assays at 15 days of incubation compared 
between two cell lines expressing SETD2 shRNA constructs (left panel) or non-silencing 
(NS) control (p < 0.01 by two-tailed student’s t-test for comparison of colony number 
between control and each of the two SETD2 constructs). The right panel depicts 
representative MTT counter-stained plates at day 15.
F. Quantitation of in vitro proliferation versus time for DERL2 HSTL cells bearing SETD2 
shRNA constructs versus non-silencing control. P=0.011 by two-tailed student’s t-test 
between shRNA #2 and NS control and P=0.0018 between SETD2 shRNA #1 and NS 
control.
All error bars throughout the figure represent the standard error of the mean.
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Figure 3. STAT5B, STAT3 and PIK3CD mutations in HSTL
A. Protein domains and HSTL mutations in STAT5B, STAT3 and PIK3CD in HSTL tumors 
are shown, with each individual mutation event denoted by a shaded circle.
B. Immunoblots of phosphorylated and total STAT5B/AKT in 293T cells after 
overexpression of STAT5B HSTL mutant constructs (N642H, V712E, P702A, I704L, 
Q706L, Y665F, T628S, E438K, G492C), wild type, or GFP-overexpression/empty vector 
controls. β-tubulin was used as loading control. Blots are representative of three independent 
experiments.
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C. Immunoblots of phosphorylated and total STAT5B and AKT in DERL2 HSTL cells 
bearing PIK3CD mutant constructs (R38C, K111Q, N334K), wild type PIK3CD retroviral 
expression construct, as well as empty vector retroviral vector transfection. GAPDH was 
used as loading control. Blots are representative of three independent experiments.
D. Cell viability measurements by alamar blue fluorescence quantitation of DERL2 HSTL 
cells bearing mutant (R38C, K111Q, N334K) or wild type PIK3CD retroviral expression 
constructs (as well as empty vector retroviral vector transfection). *(p<0.05 for comparison 
between each mutant construct and wild type control by Student’s t-test).
E. DERL2 HSTL cell viability after treatment with MEK inhibitor (selumetinib 2.5 μM), PI3 
kinase inhibitor (idelalisib 10 μM), STAT5B inhibitor (CAS 285985-31-4, 50 μM) and 
vehicle control (defined as media containing the maximum concentration of DMSO as 
diluent from drug experiments) or STAT5B/PI3-kinase inhibitor combination. *(p = 0.001 
between vehicle and STAT5B inhibitor) and **(p = 0.044 between STAT5B inhibitor and 
combination inhibitor) at 96 hours of incubation.
All error bars throughout the figure represent the standard error of the mean.
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Table 1
Summary of clinical variables and survival association
Clinical characteristics, the most common copy number aberrations, treatment, and outcome statistics for the 
cohort are summarized. The number of cases with each feature are listed, as well as a percentage of the cohort, 
excluding samples with missing data for that variable. Association with survival is tested with a univariate log-
rank test and p-values are provided for the significant tests (p<0.1).
Clinical Feature Clinical/Pathological Characteristic Number of Cases (Percent)
Log-Rank Univariate Test for 
Survival Association P-value 
(NS=not significant)
Age
Median (years) 42
NS
0–35 years 23 (42)
35–50 years 16 (30)
>50 years 15 (28)
Gender
Male 48 (71)
0.054
Female 20 (29)
Race Caucasian 50 (74)
NS
African 13 (19)
Asian 4 (6)
Hispanic 1 (1)
ECOG Performance Status
0–1 21 (62)
0.002
2–4 13 (38)
LDH Level Elevated 24 (67) 0.002
TCR Type
Gamma-Delta 37 (80)
NS
Alpha-Beta 9 (20)
Chr 7 Aberration
Present 33 (49)
0.051
Absent 35 (51)
Chr 8 Aberration
Present 21 (31)
0.024
Absent 47 (70)
Treatment
Chemotherapy only 37 (93) –
Autologous or Allogenic Transplant 10 (26) 0.014
Response to Initial Treatment
CR 11 (38)
0.001
(CR vs. non-CR)PR/SD 7 (24)
NR/PD 11 (38)
Survival
Median Survival (months) 11.9
–
Median Follow-Up (months) 49.8
Alive at 6 months 35 (75)
Alive at 12 months 24 (50)
Alive at 24 months 17 (37)
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